NCT01710046 - Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions

Plaque Psoriasis

Interventions

DRUG

(CP-6890,550) Tofacitinib

2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks

DRUG

Placebo

2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks

DRUG

(CP-690,550) Tofacitinib

2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 weeks

DRUG

Placebo

2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks

Trial Locations (5)

Olympian Clinical Research, Tampa

Menter Dermatology Research Institute, Dallas

Center for Clinical Studies, Houston

Center for Clinical Studies, Houston

Dermatology Research Associates, Los Angeles